Why is Labcorp stock sliding today?
Labcorp (LH) stock fell 3.4% after-hours to $310 following CMS's proposal to cut Medicare lab reimbursements by up to 15% annually starting 2027. CMS claims this corrects overpayments, potentially saving $1B yearly. Truist raised its price target to $365 but kept a Buy rating. Quest Diagnostics faces similar headwinds. The selloff was sector-specific, with broader markets flat.
How this was made
The 30-second read
Why it matters
The announcement creates immediate downside risk for LH, with the stock down 3.4% after‑hours and uncertainty ahead of the next earnings call.
Market read
Regulatory fee cuts are a fresh catalyst for LH and peers, likely influencing short‑term trading decisions in the healthcare sector.
What to watch
Potential for CMS to adjust the schedule after stakeholder feedback could mitigate the impact.
Background
CMS aims to align Medicare lab payments with private insurer rates, targeting $1 billion annual savings.
Ticker impact
CMS released preliminary 2027 lab fee schedule proposing up to 15% reimbursement cuts, causing LH shares to slide 3.4% in after‑hours.
Further downside pressure until guidance reflects lower reimbursement rates.
The fee schedule change is a new, material regulatory action affecting a large‑cap revenue stream.
Market effects
Other clinical laboratory providers, such as Quest Diagnostics, face similar reimbursement pressure.
U.S. healthcare sector may see broader sell pressure on lab services stocks.
Limited to U.S. Medicare‑dependent providers; minimal immediate global effect.
Counterpoint
Truist raised its price target, suggesting the cuts may be offset by cost efficiencies or other growth drivers.
Key entities
- RegulatorCenters for Medicare & Medicaid Services
Issued the preliminary 2027 Clinical Laboratory Fee Schedule.
- AnalystTruist Securities
Raised LH price target to $365 despite the fee cut news.
